CONICET | Buscador de Institutos y Recursos Humanos

New therapeutic alternatives using Benzimidazole compounds have been studied for improving its in vivo physiological dissolution and consequent plasma bioavalability. The aim of this work was to compare the plasma pharmacokinetic (PK) profiles of two different Albendazole (ABZ)-based oral formulations in dogs. Formulation A: ABZ-Poloxamer 188 (P188) as solids dispersion (SD) tablets and Formulation B: conventional tablets of ABZ. Formulation A was prepared using 400mg of SD (ABZ 200mg), 732mg of LudiflashTM, 60mg of sodium crosscaramellose and 8mg of magnesium stearate. Formulation B containing only ABZ compressed powder. A previous in vitro dissolution tests were performed using 0,1N HCl, 50rpm at 37°C. The comparative PK trial was undertaken in a crossover two-phases study as follows: six health Retriever dogs (35-45kg) were randomly divided into two groups. Phase I, Group I: Three dogs, received a single dose of ABZ 25mg/kg of the Formulation A. Group II: three dogs used as control group, were dosed with 25mg/kg of ABZ formulated as conventional tablets (Formulation B). After 21 days of wash-out period the treatments were reversed and the experiment repeated as Phase II. Blood samples were taken over 24h post-treatment, and upon analysed by High Performance Liquid Chromatography. Mann-Whitney non parametric test was used for the statistical comparison. The in vitro dissolution test showed a faster dissolution of Formulation A (t15:52,37%) compared to Formulation B (t15:40,17%). The later correlated with the in vivo PK study. The area under the concentration vs time curve values (AUC) obtained for the active metabolite Albendazole Sulphoxide (ABZSO), after treated with Formulation A, showed a significant (P

enviar mensaje